Omar Eton
Hematology & Oncology · Far Rockaway, NYNPI 1275736050
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Merck accounts for 77.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $13,385 and has fallen 99.6% since, to $52 in 2024.
Across 51 payments — averaging $616.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$24K
- Foundation Medicine, Inc.$5K
- E.r. Squibb & Sons, L.L.C.$1K
- Eisai Inc.$313
- Novartis$206
- Rigel Pharmaceuticals, Inc.$122
- plus $38 from 2 others
Across 22 payments — averaging $18,640 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$395K
- Regeneron$15K
What the payments were for
- Consulting fees$9,60531%
- Speaking & faculty fees$14,77047%
- Travel & lodging$4,20013%
- Food & beverage$2,8569%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 27 | $24,338 |
| Foundation Medicine, Inc. | 4 | $5,197 |
| E.r. Squibb & Sons, L.L.C. | 12 | $1,231 |
| Eisai Inc. | 3 | $313 |
| Novartis | 2 | $206 |
| Rigel Pharmaceuticals, Inc. | 1 | $122 |
| Johnson & Johnson | 1 | $25 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$17,447
- FOUNDATIONACT$5,197
- FOUNDATIONFOCUS$5,197
- FOUNDATIONONE CDX$5,197
- FOUNDATIONONE HEME$5,197
- FOUNDATIONONE$5,197
- OPDIVO$568
- LENVIMA$219
- Tavalisse$122
- MEKINIST$120
- TAFINLAR$120
How this compares
$31,444 in reported general payments places this provider in the 85th percentile of 967 hematology & oncology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 14 | $28,193 |
| EliquisApixaban | 17 | $26,007 |
| XareltoRivaroxaban | 11 | $6,866 |
| Prednisone | 12 | $103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $13 | $26,00717 claims |
| Johnson & JohnsonXarelto | $25 | $6,86611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in Far Rockaway
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.